Proton pump inhibitors for gastrointestinal bleeding prevention after percutaneous coronary intervention: Comparing evidence in dual antiplatelet therapy

Table 2 Baseline characteristics of included observational retrospective studies

Ref.	Year	Country	Total patients (n)	PPI group (n)	Non-PPI group (n)	PPI used	DAPT agents used	Duration of study
Kang et al[31]	2025	Korea	71120	35560	35560	Non-selective PPI	PCI and DAPT	1 year
Kim et al[32]	2024	Korea	2266	1133	1133	Non-selective PPI	Aspirin and clopidogrel	15 years
Yamamoto et al[34]	2024	Japan	24563	11202	13361	Non-selective PPI	Aspirin plus clopidogrel or ticagrelor	3 years
Rossini et al[33]	2011	Italy	1328	1158	170	Omeprazole/pantoprazole/Lansoprazole	Aspirin and clopidogrel	12 months
Yasu et al[35]	2010	Japan	302	103	199	Rabeprazole	Aspirin and clopidogrel	395 days
Aihara et al[29]	2012	Japan	1000	500	500	Non-selective PPI	Aspirin and clopidogrel	1 year
Chitose et al[28]	2012	Japan	1270	331	939	Non-selective PPI	Aspirin and clopidogrel or ticagrelor	18 months
Häuptle et al[30]	2012	Switzerland	718	87	631	Non-selective PPI	Aspirin and clopidogrel	12 months

PPI: Proton pump inhibitor; DAPT: Dual antiplatelet therapy; PCI: Percutaneous coronary intervention.